Neoadjuvant chemo with mFOLFIRINOX shows survival benefit in locally advanced rectal cancer
Dr Thierry Conroy talks to ecancer at ASCO 2023 about the randomised phase 3 PRODIGE 23 trial. It found that modified FOLFIRINOX chemotherapy before chemoradiation, surgery and adjuvant chemotherapy significantly improved survival outcomes in patients with locally advanced rectal cancer, versus standard of care.
▶︎
ASCO 2023: Highlights and analysis
▶︎
9 Colon Cancer Symptoms You Should NEVER Ignore (Doctor Explains)
▶︎
ASCO 2026: Key Insights In RCC, Merkel Cell Carcinoma, and CML
▶︎
Day 2: Molecular profiling across the UK
▶︎
Day 2: Targeted therapies, immunotherapies, trial updates (ABC-10, SAFIR IMPACT)
▶︎
STAGE 4 COLON CANCER AT 31 YRS OLD | my diagnosis story part 1
▶︎
Phase 2 Study of Multi-Cancer Detection from Breath Samples
▶︎
Wenn der Tod ein Anfang ist | Die Nordreportage | NDR
▶︎
She’s 12. She Sings Aretha Franklin… Until Simon TELLS Her to Do It Acapella! 😳
▶︎
10 Early Colon Cancer Signs You Should Never Ignore
▶︎
Bladder Cancer Explained: Risk Factors, Symptoms & Treatment
▶︎
Before you Start or Refuse Cancer Therapy- WATCH THIS!
▶︎
It's NOT Memory - 5 Early Dementia Signs Everyone Misses
▶︎
Surgery or Radiotherapy for Prostate Cancer? Here's What the Evidence Shows
▶︎
Kidney Cancer / Renal Cell Carcinoma: EXPLAINED
▶︎
Tom Green: I didn’t expect to survive testicular cancer
▶︎
Warning Signs of Colon Cancer You Should Never Ignore
▶︎
Small Cell Lung Cancer/ Small Cell Carcinoma
▶︎
AI-derived pathology-based biomarker predicts benefit of LTADT with RT in localised high-risk PC
▶︎